Zosano Pharma Corp: management transactions · United States · SEC (Form 4)

About Zosano Pharma Corp

Zosano Pharma Corp. is a U.S.-based biopharmaceutical company that historically traded on the NASDAQ under the ticker ZSAN in the United States (United States). The company built its identity around a proprietary transdermal microneedle patch platform designed to deliver therapeutics rapidly through the skin, with the goal of improving onset of action, convenience, and product stability versus conventional oral or injectable dosage forms. Its headquarters and core operations were historically located in Fremont, California, placing it within one of the most active biotech clusters in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1587221/000119312514246169/d721131ds1.htm?utm_source=openai)) From a corporate history perspective, Zosano traces its technology heritage to the Macroflux platform originally developed within Alza/Johnson & Johnson. The company later evolved into an independent specialty biotech focused on microprojection drug delivery. SEC filings describe a patch-based system consisting of titanium microneedles coated with drug and delivered through a reusable hand-held applicator. The core design philosophy was to enable rapid systemic absorption while avoiding deeper nerve endings, aiming to combine patient-friendly administration with pharmacokinetic advantages. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1587221/000119312514270452/d721131ds1a.htm?utm_source=openai)) Strategically, Zosano was never a broad diversified pharma group; it was a platform company. Its best-known development program was M207, a zolmitriptan microneedle patch intended for migraine treatment. The company also referenced other potential applications for its delivery system, including collaboration opportunities in vaccines and other bioactive molecules, but the market thesis remained heavily concentrated on proving the clinical and regulatory value of its microneedle platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1587221/000158722122000010/zosanopharmacorporatepre.htm?utm_source=openai)) Competitively, Zosano operated in a niche segment of drug delivery, competing indirectly with oral, injectable, and other transdermal technologies. Its proposed advantages included rapid onset, room-temperature stability, and a simple patch-based user experience. The strategic trade-off was concentration risk: value creation depended on a small number of assets and on regulatory success, making the equity story highly binary and sensitive to FDA outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1587221/000158722120000004/a10kfy2019.htm?utm_source=openai)) A major recent event was the company’s June 2022 voluntary Chapter 11 filing in the United States, which marked a decisive shift in the investment case from operating growth toward restructuring and capital preservation. For equity investors, that means the name is best approached through a special-situation lens, with attention to SEC disclosures, insider transactions, and any restructuring-related developments rather than a conventional commercial launch narrative. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1587221/000119312522165821/d298742dex991.htm?utm_source=openai))